Following a review of its strategic options, Swedish immunology company InDex Pharmaceuticals has opted for a reverse merger with Stockholm-based Flerie Invest. 21 May 2024
Australian radiopharma developer Telix Pharmaceuticals has filed for a secondary listing, with proposals for an initial public offering in the USA. 20 May 2024
Precision oncology company Erasca, which is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, 17 May 2024
USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics has secured $125 million in financing, with the first tranche of $25 million available u 16 May 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now only weeks away, more drugmakers and research groups are lifting the lid on data 14 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.